Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01110512

Enrollment

140

Registered

2010-04-26

Start date

2010-10-31

Completion date

2011-03-31

Last updated

2010-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Insufficiency

Keywords

Improvement of CVI parameters

Brief summary

It is hoped that with the use of medication, occurs improvement of the CVI parameters, such as edema, pain, night cramps, functional discomfort, heavy feeling and that the drug test is non-inferior than the comparator.

Interventions

DRUGFlavonid

Diosmin (450 mg) + hesperidin (50 mg) 1 tablet, 2 times per day.

DRUGDaflon

Diosmin (450 mg) + hesperidin (50 mg) 1 tablet, 2 times per day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Subjects who agree to the terms described in IC; * Subjects of both genders, aged ≥ 18 and ≤ 75 years with IVC framework of the lower limbs; * Subjects with CVI ranked 3 to 5, according to CEAP scale; * Patients complaining of pain and swelling in the lower limbs secondary to IVC; * Subjects with good mental health that can respond adequately to the study questionnaires; * Subjects who agree to make any return visits for evaluation;

Exclusion criteria

* Patients with CVI classified as 0, 1, 2 or 6, according to CEAP; * Subjects who have received treatment for varicose veins as laser, medication use topical or oral (eg: brown India, coumarin, and etc.). And surgery in the 03 months preceding the study; * Patients with other diseases that may interfere with the study results: thrombosis, coagulation disorders and other diseases that the medical criteria, are important to be excluded; * Pregnant or nursing women; * Presence of any medical condition that, according to the investigator, should prevent the patient from the study; * Participation in clinical trials in the twelve months preceding the study; * Patients with serious illnesses and uncontrolled that need multidrug treatment; * Patients on diuretics of any kind, regardless of pathology (hypertension, renal or liver disease); * Values of laboratory tests appropriate security; the Hemoglobin \<10 mg / mL the creatinine\> 1.5 mg / mL; AST, ALT, GGT ≥ 2 times normal values; the platelet count below 90.000/ml; Total Bilirubin and the fractions ≤ 1.5 times the normal range. * past medical history of hypersensitivity to drugs of the same pharmacological classes of substances under investigation;

Design outcomes

Primary

Measure	Time frame	Description
Improvement of the parameters of CVI, such as edema of lower members.	90 days.	There will be 06 planned visits (V0, V1, V2, V3, V4 and V5).

Secondary

Measure	Time frame	Description
Improvement of the parameters of CVI.	90 days	There will be 06 planned visits (V0, V1, V2, V3, V4 and V5). Assessment of improvement of signs and symptoms secondary to IVC, which are: * paresthesia (tingling); * Itching; * Pain; * cramps at night; * Discomfort functional; * Heaviness.

Countries

Brazil

Contacts

Primary ContactAlexandre Frederico, Psysician

alexandre@lalclinica.com.br55 19 3829-3822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026